Dieperink H, Kemp E, Leyssac P P, Starklint H
Clin Nephrol. 1986;25 Suppl 1:S46-50.
In an effort ot elucidate the effectiveness of Cyclosporine A (CyA) relative to the toxicity, Lewis to Sprague-Dawley first and second set skin transplantation and evaluation of the renal function with clearance methods was performed. CyA 12.5 mg/kg/day delayed first set rejection from 12.3 to 15.4 days (p less than 0.001), and second set from 10.5 to 12.1 days (p less than 0.05); 25 mg/kg/day prolonged the survival times to 18.3 (p less than 0.01) and 19.5 (p less than 0.002) days, respectively. The majority of the skin grafts were still not rejected at the end of the 3 weeks CyA 25 mg/kg/day treatment in contrast to the results during 12.5 mg/kg; the second set skin graft survival was significantly better (p less than 0.01) during the higher dosage. It is concluded, that CyA is not fully immunosuppressive at the 12.5 mg/kg/day dosage. In the doses 12.5 and 25 mg/kg GFR (inulin clearance [Cin]) was reduced to 80 and 48%, respectively, of the control value; the lithium clearance (CLi) was reduced to 69 and 27%. Proximal fractional reabsorption, as calculated from 1-CLi/Cin, was increased from a control value of 82% to 86 and 92% (p less than 0.02) in the 12.5 and 25 mg/kg/day group, respectively, suggesting that CyA nephrotoxicity is due to a decrease in the glomerular ultrafiltration pressure rather than being secondary to proximal tubular damage. In conclusion, in this model there does not seem to exist a therapeutic window between nephrotoxicity and the immunological effectiveness of CyA.
为了阐明环孢素A(CyA)的有效性与毒性的关系,进行了从Lewis到Sprague-Dawley的首次和第二次皮肤移植,并采用清除率方法评估肾功能。CyA 12.5mg/kg/天使首次移植排斥反应从12.3天延迟至15.4天(p<0.001),第二次移植排斥反应从10.5天延迟至12.1天(p<0.05);25mg/kg/天分别将存活时间延长至18.3天(p<0.01)和19.5天(p<0.002)。与12.5mg/kg治疗结果相比,在25mg/kg/天的CyA治疗3周结束时,大多数皮肤移植仍未被排斥;在较高剂量时,第二次皮肤移植存活情况明显更好(p<0.01)。得出的结论是,12.5mg/kg/天剂量的CyA并非完全免疫抑制。在12.5mg/kg和25mg/kg剂量下,肾小球滤过率(菊粉清除率[Cin])分别降至对照值的80%和48%;锂清除率(CLi)降至69%和27%。根据1-CLi/Cin计算的近端分数重吸收在12.5mg/kg/天和25mg/kg/天组分别从对照值的82%增加至86%和92%(p<0.02),表明CyA肾毒性是由于肾小球超滤压降低而非继发于近端肾小管损伤。总之,在该模型中,CyA的肾毒性和免疫有效性之间似乎不存在治疗窗。